Mechanisms of Methotrexate Action in Rheumatoid Arthritis

Arthritis & Rheumatism

Volumn 37, Issue 2, 1994, Pages 193-200

  Firestein, Gary S ^a,b   Paine, Mary M ^a,b   Boyle, David L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Gensia Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; INTERLEUKIN 1BETA; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LOCALIZATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; JOINT MOBILITY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RNA ANALYSIS; SYNOVIOCYTE; SYNOVIUM;

ADULT; ARTHRITIS, RHEUMATOID; COLLAGENASES; FEMALE; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; METALLOENDOPEPTIDASES; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, MESSENGER; SYNOVIAL MEMBRANE; SYNOVITIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0028123760     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780370207     Document Type: Article

References (44)

1. Efficacy of low‐dose methotrexate in rheumatoid arthritis
2. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
3. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double‐blind study
4. A controlled two‐centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
5. Low‐dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty‐four‐week controlled clinical trial
6. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis: a randomized, double blind 26‐week trial
7. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatmend of rheumatoid arthritis
8. Low‐dose methotrexate compared with auranofin in adult rheumatoid arthritis: a thirty‐six‐week, double‐blind trial
9. Long‐term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84‐month update
10. Prospective long term follow‐up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy, and radiological progression
11. Pulse methotrexate therapy in rheumatoid arthritis: a controlled prospective roentgenographic study
12. Methotrexate treatment of rheumatoid arthritis: effects on radiological progression
13. Radiologic progression during intramuscular methotrexate treatment of rheumatoid arthritis
14. Mast cell numbers in rheumatoid synovial tissues: correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy
15. Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis: relationship to disease type, clinical activity, and antirheumatic therapy
16. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis: in vivo effects of antirheumatic drugs
17. In vivo effects of antirheumatic drugs on neutral collagenolytic proteases in human rheumatoid arthritis cartilage and synovium
18. Gene expression (collagenase, tissue inhibitor of metalloproteinase, complement, and HLA‐DR) in rheumatoid arthritis and osteoarthritis synovium: quantitative analysis and effect of intraarticular corticosteroids
19. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium
20. Localization of collagenase mRNA in rheumatoid arthritis synovium by in situ hybridization histochemistry
21. Rheumatoid arthritis: pathophysiology and implications for therapy
22. Joint destruction in arthritis: Metalloproteinases in the spotlight
23. Molecular characterization and expression of the gene encoding human erythroid‐potentiating activity
24. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between IFN‐gamma and TNF‐alpha on HLA‐DR expression, proliferation, collagenase production, and GM‐CSF production by rheumatoid arthritis synoviocytes
25. Single‐step method of RNA isolation by acid‐guanidinium‐thiocyanate‐phenol‐chloroform extraction
26. Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony‐stimulating factor‐mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis
27. Stromelysin and tissue inhibitor of metalloproteinases (TIMP) gene expression in rheumatoid arthritis synovium
28. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases‐1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin‐1 and tumor necrosis factor‐alpha on stromelysin expression
29. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells
30. The effects of methotrexate on the production and activity of interleukin‐1
31. Rescue of interleukin‐1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system
32. Studies on the effect of methotrexate on macrophage function
33. Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis
34. Interleukin‐1 mediated acceleration of type II collagen‐induced arthritis: effects of anti‐inflammatory or anti‐arthritic drugs
35. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells
36. How important are T cells in chronic rheumatoid synovitis
37. Quantitative analysis of cytokine gene expression in rheumatoid arthritis
38. 2 production by synovial cells
39. Stromelysin expression regulates collagenase activation in human fibroblasts: dissociable control of two metalloproteinases by interferongamma
40. Preferential mRNA expression of prostromelysin relative to procollagenase and in situ localization in articular cartilage
41. Interleukin‐6 induces the synthesis of tissue inhibitor of metalloproteinases‐1/erythroid potentiating activity (TIMP‐1/EPA)
42. Interleukin‐6 enhances the production of tissue inhibitor of metalloproteinases (TIMP) but not that of matrix metalloproteinases by human fibroblasts
43. Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins
44. 1958 revision of diagnostic criteria for rheumatoid arthritis